This is a news story, published by Yahoo, that relates primarily to Niemann-Pick news.
For more Niemann-Pick news, you can click here:
more Niemann-Pick newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
FDA approval. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest clinical trial news, oral drug news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
FDAReuters
•80% Informative
Niemann-Pick disease type C ( NPC ) is a rare genetic disorder that affects the nervous system and other organs.
NPC can occur between infancy and adulthood, sometimes called "childhood Alzheimer's disease" People affected by NPC only live for about 13 years .
IntraBio 's oral drug, called IB1001 , will be sold under the brand name Aqneursa .
VR Score
91
Informative language
96
Neutral language
84
Article tone
formal
Language
English
Language complexity
51
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links